Alterity Therapeutics Limited (ATHE) Stock Analysis

What Alterity Therapeutics Limited does

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Key metrics

ETFs linked to ATHE

Broad-market and Healthcare sector ETFs an investor holding Alterity Therapeutics Limited is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ATHE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Alterity Therapeutics Limited?

Alterity Therapeutics Limited trades under the ticker ATHE on NASDAQ.

Which exchange is ATHE listed on?

ATHE is listed on NASDAQ.

What sector does Alterity Therapeutics Limited operate in?

Alterity Therapeutics Limited is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ATHE in a portfolio?

PortView shows ATHE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.